Targeted drug delivery has become one of the important criteria to treat cancer efficiently without affecting the systemic route and only targeting the cancer cell. It is also important in terms of the amount of drug administered by efficiently staging the cancer. The synthetic route developed for formulating such a product should be precise, reproducible, accurate and consistent with minimum or rather negligible deviations. We have validated the method which determines the consistency of the synthetic route for a nanoformulation containing pegylated nanosilver as the carrier and pemetrexed as the targeted drug. The study we carried out shows the usefulness of this tool, and proving the concept
